5 High Growth Stocks to Buy Right Now

2. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 132

Eli Lilly and Company (NYSE:LLY) is one of the high growth stocks to buy right now. On June 14, Eli Lilly announced positive results from the Phase 3 BRUIN CLL-322 clinical trial, which evaluated the addition of Jaypirca (pirtobrutinib) to a time-limited venetoclax and rituximab regimen for patients with relapsed or refractory chronic lymphocytic leukemia/CLL or small lymphocytic lymphoma/SLL. The study met its primary endpoint, showing that the pirtobrutinib combination reduced the risk of disease progression or death by 45% compared to the control arm of venetoclax and rituximab alone.

The trial enrolled 639 patients, nearly 80% of whom had been previously treated with a covalent BTK inhibitor, making the findings highly relevant to current clinical practices. At a median follow-up of 27.3 months, the median progression-free survival/PFS in the pirtobrutinib arm had not been reached, compared to 39.7 months in the control arm. These benefits were consistent across various high-risk patient subgroups, and the pirtobrutinib combination also showed a significant advantage in the time to next treatment.

The safety profile of the regimen was consistent with the known profiles of the individual medicines, with minimal additive toxicity observed when adding pirtobrutinib. Discontinuation rates due to treatment-related adverse events were similar between the two study arms. Based on these findings, Eli Lilly and Company (NYSE:LLY) plans to submit the data to global regulatory authorities with the goal of expanding the use of Jaypirca as a potential new standard of care in previously treated CLL/SLL populations.

Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products.